Skip To Main Content
Search Search

NSW-based biomedical company Tetratherix has signed a historic co-development agreement with Chinese pharmaceutical company Link Health, which will see advances in regenerative medicine that will benefit both NSW and China.

Tetratherix and Link Health met during the 2019 NSW-Guangdong Joint Economic Meeting (JEM) and the agreement is one of the most significant trade and commercial outcomes from the meeting.

Tetratherix is a start-up based in Alexandria NSW. They have been supported by NSW Health’s Medical Devices Fund in 2018, and NSW Health’s Medical Device Commercialisation Training Program, which was delivered in partnership with Cicada Innovations. Their injectable technology repairs bone, cartilage and connective tissues, and is patented globally including in Australia, the United States and Europe.

The NSW Government is committed to supporting home-grown businesses succeed on the world stage and has provided $12 million of support through the Going Global package. Eligible businesses looking to expand export operations or start exporting for the first time can apply for an up to $10,000 Export Assistance Grant as part of the package. For more information, visit



NSW Invest Team
NSW Department of Industry